Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus" MSD Ongoing Ertugliflozin 3 MK-8835-059-00 KSH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial Celgene Completed Luspatercept (ACE 536) 3 ACE-536-B-THAL-001 KKUH
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease. Eli Lilly Terminated Prasugrel 3 H7T-MC-TADO KAUH-J
A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-06651600 AND PF 06700841 AS INDUCTION AND OPEN LABEL EXTENSION TREATMENT IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE Pfizer Completed PF-06651600 2a B7981007 NGHA-R,KKUH, King Abdulaziz Medical City NG (Jeddah)
"A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease " Janssen-Cilag International NV Ongoing Guselkumab 2 CNTO1959CRD3001 KAMC
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care Kaleido Biosciences Completed KB195 2 K020-218 KKUH
A Phase 1/2 Open-label Clinical Study of hLB-001 Gene Therapy in Pediatric Patients With Methylmalonic Acidemia Characterized by MMUT Mutations Logic Bio Therapeutics Ongoing AAV-hHA-hMUT 1, IIIb LB001-001 King Abdulaziz Medical City NG (Riyadh)
A PARTIALLY DOUBLE-BLINDED, RANDOMIZED, CONTROLLED, PLACEBO-CONTROLLED STUDY, A PHASE III TRIAL OF SAFETY AND EFFICACY OF PREMEDICATION WITH DEXMEDETOMIDINE AND MIDAZOLAM IN PEDIATRIC PATIENTS King Faisal Specialist Hospital and Research Centre Ongoing DEXMEDETOMIDINE 3 RAC# 21901310 King Faisal Specialist Hospital and Research Center (Riyadh)
"A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies " KAIMRC Ongoing HYDROXYUREA (HYDROXYCARBAMIDE) 3 CT20/008/R King Abdulaziz Medical City NG (Riyadh)
A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 GDRS (MOH) Ongoing Convalescent Plasma 2 20-COVID-19-01M KFSH-D
View 421 - 430 From 804